Holen Sie sich die Stockscreener-App
40.65
18.62%
-9.30
Vorhandelsmarkt:
40.90
0.25
+0.62%
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC's Huntington study was positive. Why did its stock fall? - Pharmaphorum
Tudor Investment Corp ET AL Grows Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
First Trust Advisors LP Grows Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTCT Stock Dips 18% Despite Positive Huntington's Disease Study Results - GuruFocus
Raymond James Financial Inc. Invests $2.20 Million in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug - insights.citeline.com
Why Did PTC Therapeutics Stock Fall On Monday Despite Mid-Stage Study For Huntington's Hits Primary Goal? - Benzinga
Leerink maintains $52 target on PTC Therapeutics stock By Investing.com - Investing.com India
Leerink maintains $52 target on PTC Therapeutics stock - Investing.com
PTC's Novartis-partnered Huntington's drug disappoints in mid-stage data reveal - FirstWord Pharma
PTC’s Huntington’s study succeeds, but accelerated approval uncertain - Endpoints News
PTC Therapeutics stock drops after Huntington’s study update - Investing.com Australia
PTC Therapeutics price target lowered to $57 from $65 at RBC Capital - TipRanks
RBC Capital Adjusts Price Target for PTC Therapeutics (PTCT) After Study Data | PTCT Stock News - GuruFocus
RBC Capital Adjusts PTC Therapeutics Price Target to $57 From $65, Maintains Outperform Rating - marketscreener.com
PTC Therapeutics (PTCT) Announces Stock Option Grants for New Employees - GuruFocus
PTC Therapeutics (PTCT) Faces Scrutiny Over Phase 2 Study Data | PTCT Stock News - GuruFocus
Earnings To Watch: PTC Therapeutics Inc (PTCT) Reports Q1 2025 Result - GuruFocus
PTC Therapeutics Reports Positive Phase 2 Study Results - TipRanks
PTC stock slides on new data for Huntington’s drug - Yahoo Finance
PTC518 shows promise in Huntington’s disease trial By Investing.com - Investing.com Canada
PTC Therapeutics Says Phase 2 Votoplam Trial in Huntington's Disease Meets Primary Endpoint - marketscreener.com
PTC Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow
PTC Therapeutics (PTCT) Announces Promising Phase 2 Results for Huntington's Treatment | PTCT Stock News - GuruFocus
PTC518 PIVOT-HD Study Achieves Primary Endpoint | PTCT Stock New - GuruFocus
PTC518 shows promise in Huntington’s disease trial - Investing.com Australia
PTC518 PIVOT-HD Study Achieves Primary Endpoint - Quantisnow
Schonfeld Strategic Advisors LLC Sells 66,953 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Nebula Research & Development LLC Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Sold by PDT Partners LLC - MarketBeat
Price T Rowe Associates Inc. MD Trims Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Teachers Retirement System of The State of Kentucky Takes $940,000 Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Aquatic Capital Management LLC - MarketBeat
Susquehanna Fundamental Investments LLC Takes Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
What is Leerink Partnrs' Forecast for PTCT FY2026 Earnings? - MarketBeat
Adage Capital Partners GP L.L.C. Increases Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Tower Research Capital LLC TRC Buys 16,110 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eagle-Tribune
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PTCT Stock News - GuruFocus
Invesco Ltd. Purchases 57,582 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Canada Pension Plan Investment Board Buys New Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by Wells Fargo & Company MN - MarketBeat
Guggenheim Capital LLC Has $880,000 Stock Position in PTC Therapeutics, Inc. (NASDAQ:PTCT) - MarketBeat
Phenylketonuria Clinical Trial Pipeline Appears Robust With - GlobeNewswire
Phenylketonuria Clinical Trial Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight | DelveInsight - Yahoo Finance
PTC Therapeutics: Strategic Advancements and Market Opportunities Drive Buy Rating - TipRanks
PTC and Jazz Pharmaceuticals among latest firms to win EU backing for drugs - MSN
PTC Therapeutics (NASDAQ:PTCT) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):